Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
NASDAQ:ECYT
Delisted

Endocyte Fund Price (Quote)

$23.99
+0 (+0%)
At Close: Jan 18, 2019

Range Low Price High Price Comment
30 days $23.97 $24.00 Friday, 18th Jan 2019 ECYT stock ended at $23.99. During the day the stock fluctuated 0% from a day low at $23.99 to a day high of $23.99.
90 days $23.37 $24.00
52 weeks $2.81 $24.00

Historical Endocyte prices

Date Open High Low Close Volume
Oct 01, 2018 $17.99 $18.35 $17.72 $17.77 825 600
Sep 28, 2018 $17.70 $18.25 $17.62 $17.76 1 476 948
Sep 27, 2018 $17.72 $18.33 $17.36 $17.76 1 011 803
Sep 26, 2018 $18.37 $18.41 $17.53 $17.70 1 103 941
Sep 25, 2018 $18.30 $18.72 $18.30 $18.38 802 473
Sep 24, 2018 $17.46 $18.32 $17.38 $18.24 1 047 773
Sep 21, 2018 $17.62 $17.98 $17.35 $17.53 1 653 835
Sep 20, 2018 $17.53 $18.05 $17.29 $17.63 722 774
Sep 19, 2018 $17.84 $18.47 $17.45 $17.54 881 026
Sep 18, 2018 $17.52 $18.11 $17.28 $17.97 1 307 166
Sep 17, 2018 $18.36 $18.42 $17.30 $17.46 2 084 046
Sep 14, 2018 $18.86 $19.16 $18.29 $18.37 1 515 879
Sep 13, 2018 $18.82 $19.05 $18.20 $19.03 1 848 247
Sep 12, 2018 $20.00 $20.18 $18.55 $18.91 5 679 625
Sep 11, 2018 $18.14 $19.73 $17.90 $19.55 2 929 922
Sep 10, 2018 $19.30 $19.60 $17.20 $18.89 6 732 573
Sep 07, 2018 $17.74 $18.78 $16.87 $16.96 2 226 960
Sep 06, 2018 $18.60 $18.91 $17.53 $17.59 2 943 064
Sep 05, 2018 $19.97 $20.34 $18.89 $19.01 1 686 600
Sep 04, 2018 $19.80 $20.85 $19.64 $19.95 1 915 088
Aug 31, 2018 $19.86 $19.96 $18.95 $19.72 938 045
Aug 30, 2018 $18.59 $19.31 $18.08 $19.26 1 534 209
Aug 29, 2018 $19.94 $20.60 $18.29 $18.65 2 240 809
Aug 28, 2018 $19.32 $20.01 $19.18 $19.83 2 321 705
Aug 27, 2018 $18.45 $19.78 $18.45 $19.25 1 677 505
Click to get the best stock tips daily for free!

About Endocyte

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trials to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of ad... ECYT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT